靶向α治疗的临床转化:安全性、剂量学、辐射防护与监管考量
本文综述靶向α治疗(TAT)临床转化的证据,指出镭-223具有最强的临床与监管基础,而锕-225、铅-212、钍-227、砹-211、铋-213等处于不同开发阶段。α粒子高线性能量传递但组织射程仅数个细胞直径,给剂量学、生产质控、污染控制、患者管理、废物处置和监管带来挑战。证据支持在选定适应症和试验中谨慎开展TAT,但常规应用仍受核素供应、产品特异性剂量学、器官毒性、生产标准化、长期安全性数据和监管异质性限制。
要点
- 镭-223临床与监管基础最强,其他α核素药物处于不同开发阶段。
- α反冲与子体核素再分布是剂量学和辐射防护的关键挑战。
- TAT常规应用受核素供应、器官毒性、生产标准化和监管异质性限制。
核心结论
- 证据支持在选定适应症和试验中谨慎开展TAT,但常规应用仍受多重因素限制。
研究设计与样本
- 本文为综述,分析靶向α治疗临床转化中安全性、剂量学、辐射防护和监管的证据,区分已确立实践与新兴概念及机构特定选择。
主要发现
- 镭-223具有最强的临床与监管基础,锕-225、铅-212、钍-227、砹-211和铋-213药物处于不同开发阶段。
- α粒子高线性能量传递且组织射程仅数个细胞直径,可致密集局部能量沉积但给剂量学、生产、质控、污染控制、患者管理、废物处置和监管带来挑战。
- 综述重点关注α反冲与子体核素再分布、基于MIRD和小尺度剂量学、途径依赖性放射性核素杂质、良好生产规范、内污染预防、肾与唾液腺毒性、骨髓风险及辖区特定监管要求。
- 定量成像、蒙特卡罗输运和体素剂量学已进入专科工作流程,而概念验证性自动化和更愿景性的人工智能应用仍被区分对待。
临床怎么用
- 在选定适应症和试验中,TAT应在严格治理框架下开展。
局限性
- 常规使用受放射性核素供应、产品特异性剂量学、器官毒性、生产标准化、长期安全性数据和监管异质性限制。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Targeted alpha therapy (TAT) has moved from a largely experimental approach into clinically relevant radiopharmaceutical therapy, although evidence varies across radionuclides and products. Alpha particles combine high linear energy transfer with a tissue range of only a few cell diameters. This permits dense, localized energy deposition but creates challenges in dosimetry, radiopharmaceutical production, quality control, contamination control, patient management, waste disposal, and regulation. This review examines evidence for safe clinical implementation and distinguishes established practice from emerging concepts and institution-specific choices. Radium-223 has the strongest clinical and regulatory foundation; actinium-225, lead-212, thorium-227, astatine-211, and bismuth-213 agents are at different stages of development. Particular attention is given to alpha recoil and daughter-radionuclide redistribution, Medical Internal Radiation Dose (MIRD)-based and small-scale dosimetry, route-dependent radionuclidic impurities, good manufacturing practice, prevention of internal contamination, renal and salivary-gland toxicity, marrow risk, and jurisdiction-specific regulatory requirements. Technologies already entering specialist workflows, including quantitative imaging, Monte Carlo transport, and voxel dosimetry, are distinguished from proof-of-concept automation and more aspirational artificial-intelligence applications. Evidence supports carefully governed TAT in selected indications and trials, but routine use remains limited by radionuclide supply, product-specific dosimetry, organ toxicity, manufacturing standardization, long-term safety data, and regulatory heterogeneity.
引用
- Jokar N, Pashazadeh A, Juweid ME, et al. Clinical translation of targeted alpha therapy: safety, dosimetry, radiation protection, and regulatory considerations. Semin Nucl Med. 2026. PMID: 42881022. doi:10.1053/j.semnuclmed.2026.09.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。